Actualités sur Health

10.02.2005 – 14:18
LAB International Inc
LAB International Acquires Scantox
Laval, Canada (ots/PRNewswire) - - Danish Contract Research Organization Will Help Double LAB Research's Revenues LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company with a focus on inhalation delivery, today announced it has acquired all shares of Scantox, Biologisk Laboratorium A/S (Denmark), the leading Scandinavian, non- clinical contract research organization, for a total cash consideration of 28 million ...
plus
09.02.2005 – 12:10
Sequenom, Inc.
SEQUENOM and Iceland Genomics Announce Research Collaboration to Investigate Role of Cancer Predisposition Genes
San Diego, California and Reykjavik, Iceland (ots/PRNewswire) - - Continues Research to Validate Significance of SEQUENOM's Portfolio of Breast Cancer Genetic Discoveries SEQUENOM, Inc. (NASDAQ: SQNM) and Iceland Genomics Corporation (Iceland Genomics), a privately-held company, entered into a ...
plus
03.02.2005 – 20:43
Align Technology, Inc.
Align Technology Files Lawsuit
Santa Clara, California (ots/PRNewswire) - Align Technology, Inc. (Nasdaq: ALGN), the inventor of Invisalign(R), a proprietary method of straightening teeth without wires and brackets, today filed a multi-claim lawsuit in San Francisco County Superior Court against defendants OrthoClear, Inc., OrthoClear Holdings, Inc., Muhammad Ziaullah Chishti, Bao Tran, Peter Riepenhausen, Joe Breeland, Jeff Tunnell, Christopher Kawaja, and Charles Wen. Among other things, the lawsuit ...
plus
01.02.2005 – 12:13
Medex
Medex Announces Tsunami Relief Efforts
Carlsbad, California (ots/PRNewswire) - - Medex Commits More Than US$1.4 Million in Medical Product Contributions Medex, a global manufacturer and marketer of medical devices, announced today that it has authorized medical product donations of more than US$1.4 million to assist with relief efforts throughout tsunami-affected countries and other regions requiring assistance. Working through AmeriCares, ...
plus
27.01.2005 – 17:11
Roche Pharmaceuticals
Avastin(R) Extends Survival in Patients With Advanced Colorectal Cancer; New Data Supports Its Combination With Widely Prescribed Chemotherapy
Basel, Switzerland (ots/PRNewswire) - - Study adds to the body of evidence showing the benefits of Avastin with different colorectal cancer treatment regimens A new study, presented for the first time today, shows Avastin(R) (bevacizumab, rhuMAb-VEGF) significantly increases survival in patients with ...
plus
27.01.2005 – 17:03
Roche Pharmaceuticals
Breakthrough Drug Tarceva Provides New Hope for Patients With Advanced Pancreatic Cancer
Basel, Switzerland (ots/PRNewswire) - - New data shows significant improvement in overall survival when Tarceva is added to chemotherapy New data, presented for the first time today, have shown that adding Tarceva (erlotinib) to chemotherapy improves survival in patients with locally advanced or metastatic pancreatic cancer(1). This is the second cancer type ...
plus

26.01.2005 – 20:51
IBCSG
Letrozole Reduces the Risk of Post-Surgery Recurrence of Early Breast Cancer When Compared With Tamoxifen, Study Shows
St. Gallen, Switzerland (ots/PRNewswire) - In postmenopausal women with early breast cancer, letrozole offers better post-surgery protection against breast cancer recurrence than does tamoxifen, the current standard of care, according to data presented today at the Primary Therapy of Early Breast Cancer 9th ...
plus
26.01.2005 – 20:50
IBCSG
Web Cast of Landmark, Independent Trial Data from Major Breast Cancer Meeting
St. Gallen, Switzerland (ots/PRNewswire) - - Promising News for Breast Cancer Patients - Web Cast Briefing Available at http://www.ibcsg.org/index.shtm WHAT: BIG 1-98: First results and implications. A landmark, independent study found that letrozole, a leading aromatase inhibitor also known as Femara, demonstrated ...
plus
26.01.2005 – 14:03
Isotechnika Inc.
Isotechnika Completes Recruitment for Phase III Psoriasis Trial
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has completed recruitment for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247. Of the 400 subjects enrolled in the trial, 207 subjects have commenced treatment. The Company received a "No Objection Letter" from Health Canada on December 1, 2004 and commenced the trial on December 2, 2004. ...
plus
18.01.2005 – 15:33
Kodak
Kodak to Purchase OREX, Leader in Computed Radiography Products for Specialty Markets
Rochester, New York (ots/PRNewswire) - - Acquisition Broadens Kodak's CR Portfolio; Provides Foundation for Continued Growth - With Photo Eastman Kodak Company today announced it has entered into an agreement to acquire OREX Computed Radiography Ltd., a leading provider of compact, robust computed radiography systems that enable medical practitioners to ...
plus
17.01.2005 – 08:25
PharmaMar
PharmaMar's Fifth Novel Compound, Zalypsis(R), Enters Clinical Development
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Zalypsis(R) (PM00104/50), its fifth new marine derived compound, has begun Phase I clinical trials, already in patients, for the treatment of solid tumours. Zalypsis is a novel chemical entity related to the marine natural compounds Jorumycin and the family of Renieramycins, obtained from molluscs ...
plus
17.01.2005 – 07:33
sanofi-aventis Group
US FDA Licenses Menactra(TM) Vaccine(Meningococcal Groups A, C, Y and W-135 Polysaccharide Diphtheria Toxoid Conjugate) For Protection Against Meningococcal Infection
Paris (ots/PRNewswire) - - Menactra Vaccine is Safe and Effective in Preventing Potentially Deadly Meningococcal Disease Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra(TM) (Meningococcal [Groups A, ...
plus

14.01.2005 – 07:31
Roche Pharmaceuticals
Innovative Roche cancer medicine Avastin approved in EU
Basel, Switzerland (ots/PRNewswire) - - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer Roche today announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer. Roche will now make Avastin available ...
plus
06.01.2005 – 19:02
SurfAid International
Funds Urgently Needed for SurfAid Emergency Medical Relief for Nias Island, Indonesia
Queensland, Australia (ots/PRNewswire) - The people of Nias and surrounding islands have been some of the worst affected by the Earthquake Tsunami disaster that struck on 26 December. Nias lies around 125 km off the west coast of Northern Sumatra in Indonesia and, similar to Banda Aceh, encountered the full force of the Earthquake and Tsunami. Local reports ...
plus
06.01.2005 – 01:14
Graduate Management Admission Council
Intellectual Property Protection for GMAT Upheld in China Court Ruling
Mclean, Virginia (ots/PRNewswire) - In a precedent-setting decision released on December 27, 2004, the Beijing High Court (the highest court in Beijing, China) has ruled in favor of the Graduate Management Admission Council(R) in the Council's copyright infringement suit against the Beijing New Oriental School (BNOS). The case is one of the first intellectual ...
plus
03.01.2005 – 11:41
Australian Embassy - Thailand
Disaster Victim Identification Process Update
Phuket, Thailand (ots/PRNewswire) - The Thai government is in the process of establishing an international standard post mortem and ante-mortem identification centre in Phuket as the processing of victims of the tsunami that hit Thailand gets underway. There are now disaster victim identification (DVI) teams from 19 countries in Thailand working under the command of General Nopadol of the Royal Thai Police, the ...
plus
23.12.2004 – 12:59
Baxter Healthcare SA
Baxter Announces European Union Expanded Approval of ADVATE for use in Children With Haemophilia A Less Than Six Years Old
Zurich, Switzerland (ots/PRNewswire) - Baxter Healthcare S.A. announced today that the European Commission has granted expanded approval of ADVATE(R) (Octocog Alfa Recombinant Coagulation Factor VIII), for use in children with haemophilia A under six years of age. This expanded approval was granted on the ...
plus
22.12.2004 – 14:05
Abbott Laboratories
Abbott Announces Regulatory Submissions for Use of HUMIRA(R) (adalimumab) as First-Line Treatment for Rheumatoid Arthritis
Abbott Park, Illinois (ots/PRNewswire) - - HUMIRA Data Shows Slowed Joint Damage in Pivotal Study Abbott (NYSE: ABT) announced it has simultaneously submitted a Type II Variation to the European Medicines Agency (EMEA) and a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug ...
plus

17.12.2004 – 14:09
Abbott Laboratories
Abbott Announces European and U.S. Regulatory Submissions for Humira(R) as Treatment for Psoriatic Arthritis
Abbott Park, Illinois (ots/PRNewswire) - - First expansion into new disease for rheumatoid arthritis drug HUMIRA Abbott (NYSE: ABT) announced it has simultaneously submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) and a supplemental Biologics License Application ...
plus
17.12.2004 – 12:53
AstraZeneca GmbH
Gefitinib (Iressa(TM)) Lung Cancer ISEL Trial Shows no Overall Survival Advantage in a Highly Refractory Population
London (ots/PRNewswire) - AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer (ISEL) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in the overall ...
plus
15.12.2004 – 07:03
AstraZeneca GmbH
Historic Breast Cancer Awareness Initiative Meets Global Need for Breast Cancer Information
London (ots/PRNewswire) - - 'Redefining Hope and Beauty' Campaign Surpasses All Expectations Breast cancer charities from around the world are today celebrating the success of the world's first truly global breast cancer awareness campaign - 'Redefining Hope and Beauty'. In the first few weeks since its historic launch, the campaign has already surpassed ...
plus
13.12.2004 – 08:06
AstraZeneca GmbH
New Data for Faslodex (TM) Demonstrate Efficacy Following Aromatase Inhibitor Therapy
San Antonio Breast Cancer Symposium, California (ots/PRNewswire) - - New Results From Two Phase II Trials Demonstrate Efficacy and Tolerability for 'Faslodex' Following Progression on aromatase Inhibitor Therapy - Webcast of Data Available on www.astrazenecapressoffice.com Important new data from two studies presented at the 27th Annual San Antonio Breast ...
plus
13.12.2004 – 08:04
AstraZeneca GmbH
Summary of Key 'Arimidex' (Anastrozole) Data From the 27th Annual San Antonio Breast Cancer Conference
San Antonio, Texas (ots/PRNewswire) - - New Trial Results Offer More Choice for More Women With Breast Cancer The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Completed Treatment Analysis(1),(2): Presented by Professor Anthony Howell and simultaneously published via fast-track peer-review in ...
plus
10.12.2004 – 12:13
AstraZeneca GmbH
More Choice for More Women
San Antonio, Texas (ots/PRNewswire) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented at the 27th San Antonio Breast Cancer Symposium (SABCS), 8 - 11 December. The webcast explores the latest developments in the treatment of postmenopausal women with early ...
plus

09.12.2004 – 15:58
LAB International Inc
LAB International Shares Trading on the Frankfurt Stock Exchange
Laval, Quebec (ots/PRNewswire) - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the ...
plus
09.12.2004 – 14:06
Baxter International Inc.
Baxter Suspends Enrollment in European Clinical Trial for PreFluCel
Deerfield, Illinois (ots/PRNewswire) - Baxter International Inc. (NYSE: BAX) announced today that it has voluntarily suspended enrollment in the Phase II/III clinical study currently underway in Europe of its PreFluCel influenza vaccine, due to a higher than expected rate of mild fever and associated symptoms in the clinical trial participants. "In developing a ...
plus
09.12.2004 – 13:32
Austrian Breast and Colorectal Cancer St
Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Breast Cancer Patients Treated with Hormone Therapy
San Antonio, Texas (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
plus
07.12.2004 – 19:58
Medicsight Inc.
Medicsight Inc. Files American Stock Exchange Application, Appoints Three Independent Directors, Establishes Audit Committee
London (ots/PRNewswire) - Medicsight Inc. (OTC Bulletin Board: MSHT) announced today that on November 30, 2004 it forwarded its application to transfer the Company's listing from the OTC Bulletin Board to the American Stock Exchange to Cohen Specialists LLC, who deposited it with the American Stock Exchange on ...
plus
07.12.2004 – 16:13
Austrian Breast and Colorectal Cancer St
Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Breast Cancer: Patients Treated with Hormone Therapy
San Antonio (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
plus
06.12.2004 – 18:16
LAB International Inc
LAB International to Initiate Phase II Trial for GHRH
Laval, Canada (ots/PRNewswire) - - Malnutrition in Patients With Late Pre-end-stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that, after completion of a successful dose-response trial, it has selected the first clinical indication for which it intends to evaluate ...
plus

Précédent85868788899091929394Suivant